Endocrine Abstracts

Objectives: BRAFV600E mutation is present in 50% of aggressive papillary thyroid carcinoma(PTC). TERT promoter (pTERT) mutations (C228T, C250T) are related to cancer growth and reduced overall- and disease-free survivals in differentiated thyroid carcinomas(DTC). We report a patient with an extremely aggressive PTC presenting in the primary lesion two pTERT mutations (C228T and C250T), and absence of BRAFV600E.<p class="abstext"...